Sana Biotechnology, Inc.
A developer of engineered cell therapies, Sana Biotechnology works to repair or replace damaged cells in the body using its "hypoimmune" technology, which masks cells so a patient's immune system won't reject them. Founded in 2018 by former leaders of the CAR T-cell pioneer Juno Therapeutics, the company takes its name from the Latin word "sana," meaning healthy or sound. Its lead programs are off-the-shelf CAR T-cell therapies in development for autoimmune diseases like lupus.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Robert Nelsen | 13G/APassive | 15.4% | 46.17M | Aug 14, 2026 |
| ARCH Venture Fund IX, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Fund IX Overage, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Fund X, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Fund X Overage, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Partners IX, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Partners IX Overage, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Partners X Overage, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Partners X, L.P. | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |
| ARCH Venture Partners IX, LLC | 13G/APassive | 15.3% | 45.86M | Aug 14, 2026 |